Crispr Therapeutics AG (NASDAQ:CRSP) was the recipient of unusually large options trading on Thursday. Stock investors acquired 1,168 put options on the company. This represents an increase of 1,986% compared to the typical volume of 56 put options.
Several analysts have recently commented on the company. Oppenheimer assumed coverage on Crispr Therapeutics in a research note on Thursday, December 7th. They issued a “hold” rating for the company. BidaskClub upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Piper Jaffray Companies assumed coverage on Crispr Therapeutics in a research note on Friday, December 22nd. They issued an “overweight” rating for the company. SunTrust Banks restated a “hold” rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research note on Friday, November 10th. Finally, Cann restated a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Crispr Therapeutics has an average rating of “Buy” and a consensus target price of $22.38.
In other news, insider Tyler Dylan-Hyde sold 15,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $18.90, for a total value of $283,500.00. Following the completion of the sale, the insider now directly owns 130,204 shares in the company, valued at approximately $2,460,855.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $18.98, for a total value of $21,114,225.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,076,167 shares of company stock valued at $40,049,167. Company insiders own 39.98% of the company’s stock.
Crispr Therapeutics (NASDAQ CRSP) opened at $26.81 on Friday. Crispr Therapeutics has a 1 year low of $11.63 and a 1 year high of $28.50. The firm has a market cap of $1,230.00 and a PE ratio of -83.78.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The business had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. During the same period in the previous year, the business posted ($2.77) EPS. Crispr Therapeutics’s revenue was up 54.2% compared to the same quarter last year. equities analysts predict that Crispr Therapeutics will post -2.46 earnings per share for the current year.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.